Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug? → HUGE BUY ALERT: Move Fast, Musk... (From Stansberry Research) (Ad) Hosted by MarketBeat StaffNovember 28, 2023 Share Share Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.8779 of 5 stars$760.00-1.5%0.68%111.93NVONovo Nordisk A/S2.0354 of 5 stars$128.42-0.2%1.04%44.28 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatDid Intel Just Dethrone Nvidia?from Chaikin Analytics8 Retail Stocks to Own For the Long Haulfrom MarketBeatTrump’s “Tax Free” Retirement Strategy from Gold Safe Exchange7 Uranium Stocks That Can Fuel a Growth Portfolio in 2024from MarketBeatAmerica’s worst nightmare?from Porter & Company7 Stocks with High Short Interest - Market Getting These Right?from MarketBeat Crafting Your Portfolio's Magnificent Seven: Top Stocks for 2024MarketBeat gives you seven stocks that you should be looking at to create your own Magnificent Seven in 2024.Recent VideosLucid’s Stock Price Still in ReverseRoblox Reality Check: Why the Metaverse Isn't Saving the Stock!Palantir Stock Solid Earnings, Sudden Drop Featured Articles and Offers3 Stocks Nancy Pelosi Has Been BuyingPosted May 10, 2024View 3 Stocks Nancy Pelosi Has Been BuyingMy system predicted the BA collapse – now it’s issuing an AI warningFrom Chaikin Analytics(Ad)View My system predicted the BA collapse – now it’s issuing an AI warningMU Nears Breakout as Analysts Continue to Pound the TablePosted May 8, 2024View MU Nears Breakout as Analysts Continue to Pound the Table3 Affordable Stocks That Won’t Stay Down Much LongerPosted May 13, 2024View 3 Affordable Stocks That Won’t Stay Down Much LongerBounce Alert: 3 Large Caps With RSIs Too Good To IgnorePosted May 10, 2024View Bounce Alert: 3 Large Caps With RSIs Too Good To IgnoreCharles Payne Demystifies OptionsFrom Unstoppable Prosperity(Ad)View Charles Payne Demystifies Options Search Videos: Search Articles Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hosted by MarketBeat StaffNovember 28, 2023 Share Share Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.8779 of 5 stars$760.00-1.5%0.68%111.93NVONovo Nordisk A/S2.0354 of 5 stars$128.42-0.2%1.04%44.28 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatDid Intel Just Dethrone Nvidia?from Chaikin Analytics8 Retail Stocks to Own For the Long Haulfrom MarketBeatTrump’s “Tax Free” Retirement Strategy from Gold Safe Exchange7 Uranium Stocks That Can Fuel a Growth Portfolio in 2024from MarketBeatAmerica’s worst nightmare?from Porter & Company7 Stocks with High Short Interest - Market Getting These Right?from MarketBeat